EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors

Boris Klebansky, Marina Backer, Vitaliy Gorbatyuk, Olga Vinogradova iD, Joseph Backer

Biomolecules · 2024

DOI: 10.3390/biom14050597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Boris Klebansky und 4 weiteren Autor:innen. Beteiligte Einrichtung: BioPredict Inc., 4 Adele Ave., Demarest, NY 07627, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Peptides, Programmed Cell Death 1 Receptor, Programmed Cell Death 1 Ligand 2 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current anti-cancer immune checkpoint therapy relies on antibodies that primarily target the PD-1/PD-L1(-L2) negative regulatory pathway. Although very successful in some cases for certain cancers, these antibodies do not help most patients who, presumably, should benefit from this type of therapy. Therefore, an unmet clinical need for novel, more effective drugs targeting immune checkpoints remains. We have developed a series of high-potency peptide inhibitors interfering with PD-1/PD-L1(-L2) protein–protein interaction. Our best peptide inhibitors are 12 and 14 amino acids long and show sub-micromolar IC50 inhibitory activity in the in vitro assay. The positioning of the peptides within the PD-1 binding site is explored by extensive modeling. It is further supported by 2D NMR studies of PD-1/peptide complexes. These results reflect substantial progress in the development of immune checkpoint inhibitors using peptidomimetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsPeptidesProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 Ligand 2 ProteinHumansProtein BindingB7-H1 AntigenBinding SitesNeoplasms

Stichwörter der Autor:innen

FRETNMRPD-1PD-L1PD-L2inhibitorsmodeling

Substanzen

Immune Checkpoint InhibitorsPeptidesProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 Ligand 2 ProteinPDCD1LG2 protein, humanPDCD1 protein, humanB7-H1 Antigen

Autor:innen und Institutionen

  • BioPredict Inc., 4 Adele Ave., Demarest, NY 07627, USA.
  • SibTech Inc., 115A Commerce Drive, Brookfield, CT 06804, USA.
  • Center for Open Research Resources & Equipment, University of Connecticut, Storrs, CT 06269-3060, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269-3092, USA.

ORCID-Profile: Olga Vinogradova

Zitieren

APA

Klebansky, B., Backer, M., Gorbatyuk, V., Vinogradova, O., & Backer, J. (2024). In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors. Biomolecules. https://doi.org/10.3390/biom14050597

Vancouver

Klebansky B, Backer M, Gorbatyuk V, Vinogradova O, Backer J. In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors. Biomolecules. 2024. doi:10.3390/biom14050597

BibTeX
@article{Klebansky2024,
  author = {Klebansky, Boris and Backer, Marina and Gorbatyuk, Vitaliy and Vinogradova, Olga and Backer, Joseph},
  title = {In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14050597}
}
Kostenlos starten →